David C. Fajgenbaum is an American immunologist, physician-scientist, and author who transformed the treatment of Castleman disease after nearly dying from the illness himself. An associate professor at the University of Pennsylvania, he co-founded the Castleman Disease Collaborative Network and Every Cure, pioneering AI-driven drug repurposing.

His memoir, Chasing My Cure, chronicles his journey from patient to innovator, advancing treatments for rare diseases and earning global recognition including TIME100 Health 2025.

David C. Fajgenbaum is an American immunologist, physician-scientist, and author who transformed the treatment of Castleman disease after nearly dying from the illness himself. An associate professor at the University of Pennsylvania, he co-founded the Castleman Disease Collaborative Network and Every Cure, pioneering AI-driven drug repurposing.

His memoir, Chasing My Cure, chronicles his journey from patient to innovator, advancing treatments for rare diseases and earning global recognition including TIME100 Health 2025.

Dr. Vassileva has decades of experience managing complex multi-stakeholder biomedical research programs. She spent most of her career in the nonprofit sector, leading the Science Team at the Arthritis Foundation, and working at the Foundation for NIH and the American Association for the Advancement of Science.

She was also on the leadership teams of two health research organizations, serving as project director on multiple government contracts. Her areas of expertise include musculoskeletal, metabolic, immunity and inflammation disorders, as well as patient engagement. She received her PhD in Biochemistry and Cell Biology from Johns Hopkins.

Dr. Vassileva has decades of experience managing complex multi-stakeholder biomedical research programs. She spent most of her career in the nonprofit sector, leading the Science Team at the Arthritis Foundation, and working at the Foundation for NIH and the American Association for the Advancement of Science.

She was also on the leadership tasks of two health research organizations, serving as project director on multiple government contracts. Her areas of expertise include musculoskeletal, metabolic, immunity and inflammation disorders, as well as patient engagement. She received her PhD in Biochemistry and Cell Biology from Johns Hopkins.

Dr. Gupta was appointed as President of GATC Health in February 2025. He served as the first medical doctor to serve as the White House Director of National Drug Control Policy and lead the Office of National Drug Control Policy (ONDCP), a component of the Executive Office of the President, from 2021 until January 2025.

He previously served as a local public health official and as the West Virginia Health Commissioner under two governors, where he led the opioid crisis response and launched a number of pioneering public health initiatives. He is currently a practicing physician and clinical professor at Georgetown University Medical School.

Tomas J. Philipson is an economist who served as the Acting Chairman of the Council of Economic Advisers in the Trump administration. He departed from the position and the Council at the end of June, 2020, to return to the University of Chicago where he holds the Daniel Levin Chair in Public Policy.

He has been a visiting faculty member at Yale University and a visiting fellow at The World Bank. Philipson served in the George W. Bush administration as the senior economic advisor to the Commissioner of Food and Drugs (the head of the Food and Drug Administration), and subsequently as the senior economic advisor to the head of the Centers for Medicare and Medicaid Services.

Bio coming soon.

Bio coming soon.

Brad Jordan is the Associate Vice President of Regulatory Policy and Strategy at Eli Lilly, where he is responsible for the regulatory policy strategy for Lilly's cardiometabolic and immunology therapeutic areas.

Bio coming soon.

Bio coming soon.

Katie Truong is the Senior Vice President & Managing Director of DIA Americas and the Global Head of Business Operations. In her role, Katie focuses on driving growth, optimizing operations, and enhancing business performance. With experience spanning various industries, including government, design, and professional services, she brings a wealth of knowledge to DIA. Katie holds a Bachelor of Arts degree with High Distinction from the University of Virginia and an MBA from New York University Stern School of Business, specializing in strategy, leadership, and change management.

Bio coming soon.

Eli Weinberg is a leader in Bain's Life Sciences and Private Equity practices. He is an advisor and thought partner to life science innovators in biopharma, diagnostics, and medtech, as well as investors active in those areas.

He has more than two decades of experience spanning academia, biotech, and consulting across the US, Europe, Japan, China, and South Korea.